Ghent, Belgium – 1 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022. The management team will host a...Read More